Relmada Therapeutics GAAP EPS of -$1.31

Nov. 10, 2022 4:22 PM ETRelmada Therapeutics, Inc. (RLMD)By: Preeti Singh, SA News Editor
  • Relmada Therapeutics press release (NASDAQ:RLMD): Q3 GAAP EPS of -$1.31.
  • As of September 30, 2022, the company had cash, cash equivalents, and short-term investments of approximately $184.2 million, compared to cash, cash equivalents, and short-term investments of approximately $211.9 million at December 31, 2021.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.